The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.
November 23rd 2024
With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.
November 18th 2024
November 18th 2024
November 16th 2024
In "Getting Past Denial — The High Cost of Health Care in the United States," the authors observe, again, Jack Wennberg's (Dartmouth) dictum written about extensively at the end of the last century and earlier—the cost differences between regions and practices may be unwarranted.
Medication nonadherence and adverse outcomes in CAD patients
February 18th 2009Nonadherence to beta blockers, statins, or angiotensin-converting enzyme inhibitors is common (21%-29%) among patients with coronary artery disease (CAD). Patients who do not adhere to their medication regimens are at increased risk of mortality, cardiovascular hospitalizations, and revascularization procedures; thus, medication nonadherence should be a target for quality improvement interventions to maximize the outcomes of CAD patients.
Nonadherence to cardiac medications: An important consideration
In a well-done recent study, Dr P. Michael Ho and colleagues confirm previous data and clinical observations that many patients are nonadherent to their cardiac medications, and, importantly, this nonadherence adversely impacts outcomes, including cardiovascular mortality.
Managed Care 101 in 2010 (Part XII): "One Cannot Manage What One Does Not Measure"
January 16th 2009There should be a "clarion call to action for universal health coverage. But expanded coverage needs to be coupled with comprehensive change in how health care is provided and how it is reimbursed," said Dr. Steven Safyer.
Can You Use Your Own Stem Cells to Treat Heart Failure?
Researchers at the Methodist Hospital in Houston, TX; Baylor University Medical Center in Dallas, TX; and The University of Utah School of Medicine in Salt Lake City, UT, are enrolling patients in a new clinical trial designed to help find the answer to that question.
Lifetime risk of atrial fibrillation
September 24th 2008Using data from 8,725 participants in the Framingham Heart Study who were followed for 176,166 person-years, we estimate that the lifetime risk of developing atrial fibrillation (AF) is 1 in 4 for men and women aged 40 years and older. Even when there is no antecedent congestive heart failure or myocardial infarction, the lifetime risk of AF is high (1 in 6). This significant lifetime risk highlights the major public health problem resulting from AF and the need for further study into causes, prevention, and treatment.
Sudden death in patients with myocardial infarction
September 22nd 2008We evaluated the risk and timing of sudden death among high-risk patients after myocardial infarction (MI). Among survivors of acute MI with reduced left ventricular systolic function or heart failure, or both, the risk of sudden death from cardiac causes was highest in the first 30 days after MI. These findings indicate a need for early intervention to prevent sudden death during this vulnerable period.
The clinical ramifications of CIBIS III: Does the sequence of medication initiation really matter?
September 19th 2008The development of new and innovative mechanical and pharmacologic therapies for the broad spectrum of cardiovascular disease has led to dramatic changes in the makeup of clinical practice.
Laboratory monitoring for spironolactone in congestive heart failure
September 19th 2008We evaluated how well patients taking spironolactone were monitored for hyperkalemia, as well as the association between spironolactone and hyperkalemia. Only two thirds of patients received testing for serum potassium and creatinine levels, and higher baseline serum creatinine levels predicted a high risk of hyperkalemia. These results indicate that appropriate patient selection and close monitoring are essential, especially for patients with renal impairment.
Spironolactone and hyperkalemia in congestive heart failure
In 1999 Pitt and colleagues published the results of the RALES trial, an important study showing that the addition of a relatively small dose of the aldosterone antagonist spironolactone to a regimen that included angiotensin-converting enzyme (ACE) inhibitors for patients with severe congestive heart failure (NYHA Class III-IV) had a striking benefit on mortality
Ultrafiltration for heart failure
September 17th 2008We compared the use of early, minimally invasive ultrafiltration with usual care in patients with acute decompensated heart failure in a randomized controlled trial. Ultrafiltration therapy resulted in greater fluid removal than standard therapy and was shown to be a safe and effective alternative to loop diuretics for sodium and fluid homeostasis in patients with heart failure. More research is needed to identify those patients most likely to benefit from this approach.